Hepatocellular Carcinoma: A Guide to Screening and Diagnosis

Similar documents
Surveillance for Hepatocellular Carcinoma

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH

HEPATOCELLULAR CARCINOMA (HCC) RESECTION VERSUS TRANSPLANTATION. Francis Yao, M.D.

Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco

Benign Liver Tumors. Cameron Schlegel PGY-1 3/6/2013

LIVER CANCER AND TUMOURS

Hepatocellular Carcinoma: What the hepatologist wants to know

Clinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations. Chapter. Grade. CQ No. 1 Interferon Therapy

CANCER OF THE LIVER HEPATOCELLULAR CARCINOMA

Hepatocellular Carcinoma Management Guidelines

LIVER TUMORS PROFF. S.FLORET

Hepatocellular Carcinoma Treatment Decision Tree

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

THE SECOND VERSION of Evidence-based Clinical

UK Guidelines for the management of suspected hepatocellular carcinoma (HCC) in adults

Contrast-Enhanced Ultrasound (CEUS)

Optimal imaging surveillance schedules after liver directed therapy for hepatocellular carcinoma

ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions

Hepatitis C Infections in Oregon September 2014

Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview.

Geir Folvik, MD Division of Gastroenterology Department of Medicine, Haukeland University Hospital Bergen, Norway

Hepatocellular Carcinoma and Y-90 Radioembolization

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

New Data Supporting Modified RECIST (mrecist) for Hepatocellular Carcinoma. Running Title: Modified RECIST (mrecist) for Hepatocellular Carcinoma

Evaluation and Prognosis of Patients with Cirrhosis

MRI of Benign Liver Lesions and Metastatic Disease Characterization with. Gadoxetate Disodium

SBRT (Elekta), 45 Gy in fractions of 3 Gy 3x/week for 5 weeks (N=22) vs.

Hepatocellular Carcinoma (HCC)

Breast Ultrasound: Benign vs. Malignant Lesions

Treatment of Hepatic Neoplasm

Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe

What is liver cancer?

Alpha-fetoprotein

To Whipple or Not to Whipple, that is the Question: Evaluating the Resectability of Pancreatic Adenocarcinoma

COMPLICATIONS OF CIRRHOSIS COMPLICATIONS OF CIRRHOSIS OBSERVATIONS OF AN AGING HEPATOLOGIST. Philip C. Delich, M.D.

Liver Diseases. An Essential Guide for Nurses and Health Care Professionals

Characterization of small renal lesions: Problem solving with MRI Gary Israel, MD

A PATIENT S GUIDE TO ABLATION THERAPY

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 6

MANAGEMENT OF LIVER CIRRHOSIS

Kidney Cancer OVERVIEW

Management of Spontaneous Rupture of Liver Tumours

BERGEN COMMUNITY COLLEGE DIAGNOSTIC MEDICAL SONOGRAPHY PROGRAM Division of Health Professions DMS 213 SYLLABUS

Treatment Advances for Liver Cancer

Portal Vein Thrombosis. Sophia A. Virani, HMS III Gillian Lieberman, MD Beth Israel Deaconess Medical Center Department of Radiology March 2009

ABR Certifying Exams In Diagnostic Radiology. Early Results Future Considerations

June 11, 2015 Tim Halterman

Spleen. Anatomy. (Effective February 2007) (1%-5%) Normal. Related Anatomy Anterior to spleen. Medial border. Posteriorly

Leading the Way to Treat Liver Cancer

Recanalized Umbilical Vein in the Presence of Cirrhosis-Induced Portal Hypertension

Moving Beyond RECIST

Hepatocellular carcinoma: Algorithms of diagnosis and options of therapy

The State of the Liver in the Adult Patient after Fontan Palliation

Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization N = 50

POSTMENOPAUSAL ASSESS AND WHAT TO DO

Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine

Hepatocellular Carcinoma (Liver Cancer):

Cirrhosis and HCC. Dr.Abonyi Margit PhD SE 1st.Medical Clinic

Seeing the Unseen New Techniques in Vascular Imaging

Hepatocellular carcinoma: ESMO ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

Sovaldi (sofosbuvir) Prior Authorization Criteria

PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto

Patterns of abnormal LFTs and their differential diagnosis

UCLA Asian Liver Program

Indications in Hepatology and Liver Diseases

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.

AASLD PRACTICE GUIDELINE. Management of Hepatocellular Carcinoma: An Update. Surveillance and Diagnosis. Staging and Treatment of HCC

New IDSA/AASLD Guidelines for Hepatitis C

Diagnosis, staging and treatment of hepatocellular carcinoma

Challenges in gastric, appendiceal and rectal NETs Leuven,

Lenox Hill Hospital Department of Surgery General Surgery Goals and Objectives

Case Report. Central Neurocytoma. Fotis Souslian, MD; Dino Terzic, MD; Ramachandra Tummala, MD. Department of Neurosurgery, University of Minnesota

Pancreatic Cancer. The Killer that must be discovered early. Dr Alfred Kow Wei Chieh

Hepatocellular carcinoma: A comprehensive review

PROTOCOL OF THE RITA DATA QUALITY STUDY

Hepatocellular Carcinoma

Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions National Quality Strategy Domain: Effective Clinical Care

Approach to Lower Extremity Osteomyelitis. A radiologic tour of a patient encounter

Cirrhosis and HCV. Jonathan Israel M.D.

Focal Treatment of Liver Metastasis. Bjørn Skjoldbye The Gastro Unit Herlev Hospital

Frozen Section Diagnosis

Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok

EASL EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

Transcription:

February 2012 Hepatocellular Carcinoma: A Guide to Screening and Diagnosis Reid Merryman, Harvard Medical School Year III

Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 2

HCC: Epidemiology 20,000 new cases each year in the US 5 th most common cancer in men 7 th most common cancer in women Cirrhosis is present in 80-90% of patients diagnosed with HCC. Any condition leading to cirrhosis is considered an important risk factor HBV or HCV Alcoholic cirrhosis NAFLD NEJM. 2011;365:1118-27. 3

HCC: A Global Disease - Burden of disease is greatest in developing countries, specifically those where HBV is endemic. El-Serag HB. NEJM. 2011;365:1118-27. - Worldwide, half a million cases of HCC are diagnosed each year. 4

HCC: Increasing Incidence in the US El-Serag HB. NEJM. 2011;365:1118-27. The incidence of HCC in the United States has tripled in the last 30 years. 5

We have reviewed facts about risk factors and incidence of HCC. We will now discuss our index patient. 6

Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment options Summary 7

Index Patient: Clinical Presentation I 56-year-old male with a history of alcohol-induced cirrhosis with multiple complications of ESLD Diuretic resistant ascites now improved status post TIPS placement (2007). Spontaneous bacterial peritonitis (SBP) now on Bactrim prophylaxis Hepatic encephalopathy (on lactulose and rifaximin). Grade II hemorrhoids Grade I varices 8

Index Patient: Clinical Presentation II Past medical history (continued) Non-insulin dependent Diabetes mellitus Hypothyroidism Anemia Ventral hernia repair He has ultrasound surveillance every three months to evaluate his TIPS shunt and to screen for HCC. Previous ultrasounds have shown no focal lesions and AFP has been within normal limits. 9

Before continuing with our index patient, we will pause to review indications for liver ultrasound screening and concerning findings on screening exams. 10

Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment options Summary 11

HCC Surveillance We will discuss the following concepts. Who should be screened? What radiologic and non-radiologic studies should be used to screen? What results warrant additional testing? 12

HCC Surveillance: Screening population The American Association of Liver Diseases (AASLD) suggests screening in All patients with cirrhosis (annual incidence of HCC of 3-8%) Some patients with HBV (those whose annual incidence surpasses 0.2%) Asian men over 40 Asian women over 50 Africans and North African blacks Patients with a family history of HCC AASLD Practice Guideline, Management of Hepatocellular Carcinoma: An Update 13

HCC Surveillance: Evidence Zhang et al. J Cancer Res Clin Oncol. 2004;130:417 422. Evidence for screening is limited. One study randomized 18,816 people, aged 35 59 years with HBV infection or chronic hepatitis in urban Shanghai to every 6 month screening with US and AFP or no screening. Demonstrated a 37% decrease in HCC-related mortality with screening over five years. 14

HCC Surveillance: Imaging Modality Ultrasound sensitivity varies widely depending on the study (55%-89%) but is equivalent to CT in most studies and is much more cost-effective. NEJM. 2011;365:1118-27 Alimentary Pharmacology and Therapeutics. 2009;30:37-47 15

Now that we know the evidence behind ultrasound surveillance, we will examine some examples of screening ultrasound. The images include examples of cirrhotic livers and various presentations of HCC. 16

Companion Patient 1: Cirrhotic liver on US Transverse US Findings: 1. Nodular liver surface 2. Ascites Irshad et al. Curr Probl Diagn Radiol. 2012;41:43-51. 17

Companion Patient 2: Nodular liver on US Transverse US Findings: 1. Extremely nodular liver with heterogeneous appearance. A nodular appearance decreases the sensitivity of ultrasound for identifying HCC. Irshad et al. Curr Probl Diagn Radiol. 2012;41:43-51. 18

Companion Patient 3: HCC Transverse US HCC can present with 1. single mass 2. multiple masses 3. diffuse disease Classically HCC lesions are hypoechoic. PACS BIDMC 19

Companion Patient 4: HCC Transverse US HCC can present with 1. single mass 2. multiple masses 3. diffuse disease Classically HCC lesions are hypoechoic. Irshad et al. Curr Probl Diagn Radiol. 2012;41:43-51. 20

Companion Patient 5: HCC Transverse US HCC can present with 1. single mass 2. multiple masses 3. diffuse disease Classically HCC lesions are hypoechoic. Irshad et al. Curr Probl Diagn Radiol. 2012;41:43-51. 21

Companion Patient 6: HCC Transverse US However HCC can present with varying echogenicity. Findings: Two hyperechoic liver masses that were found to be HCC Irshad et al. Curr Probl Diagn Radiol. 2012;41:43-51. 22

We have seen multiple classic examples of HCC on ultrasounds. We will now examine our patient s screening ultrasound exam. 23

Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 24

Index Patient: Isoechoic lesion on US Transverse US Findings 1. Diffusely heterogenous echotexture. 2. Isoechoic lesion with hypoechoic rim. PACS BIDMC 25

Index Patient: Focal Lesion Transverse and Saggital US Findings: Isoechoic lesion with hypoechoic rim. PACS BIDMC 26

Index Patient: Lesion Dimensions Transverse and Saggital US Findings: Isoechoic lesion with hypoechoic rim measuring 1.2 x2.3 x1.2 cm. PACS BIDMC 27

Index Patient: Review of Findings Coarsened and nodular liver A suspicious mass in the right lobe of the liver (segment IVa) measuring 1.2 x 2.3 x 1.2 cm The mass is isoechoic with a hypoechoic rim. 28

Before discussing a differential diagnosis for our index patient s liver findings, we will briefly review segmental liver anatomy. 29

Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment options Summary 30

Liver Anatomy: Segment IVa Our patient s lesion was visualized in Section IVa. Medscape. http://www.medscape.com/content/2003/00/44/98/449855/449855_fig.html Ultrasoundpaedia: A portal to the world of ultrasound. http://www.ultrasoundpaedia.com/uploads/53003 31

Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 32

DDx: Focal Liver Lesion Benign liver masses 1. Cysts 2. Hemangioma 3. Focal nodular hyperplasia 4. Hepatic adenoma 5. Biliary cystadenoma 6. Abscess 7. Hematoma 8. Regenerating nodules 9. Confluent hepatic fibrosis Malignant liver masses 1. HCC 2. Metastases 3. Intrahepatic Cholangiocarcinoma 4. Lymphoma 5. Stromal tumors 33

DDx: Focal Liver Lesion -Patient has a cirrhotic liver Benign liver masses 1. Cysts 2. Hemangioma 3. Focal nodular hyperplasia 4. Hepatic adenoma 5. Biliary cystadenoma 6. Abscess 7. Hematoma 8. Regenerating nodules * 9. Confluent hepatic fibrosis * Malignant liver masses 1. HCC * 2. Metastases 3. Intrahepatic Cholangiocarcinoma 4. Lymphoma 5. Stromal tumors 34

DDx: Focal Liver Lesion -Patient has a cirrhotic liver -Isoechoic mass with hypoechoic rim Benign liver masses 1. Cysts 2. Hemangioma 3. Focal nodular hyperplasia * 4. Hepatic adenoma * 5. Biliary cystadenoma 6. Abscess 7. Hematoma 8. Regenerating nodules * 9. Confluent hepatic fibrosis * Malignant liver masses 1. HCC ** 2. Metastases 3. Intrahepatic Cholangiocarcinoma 4. Lymphoma 5. Stromal tumors 35

We have prioritized our differential diagnosis for our index patient s liver lesion based on his history and ultrasound findings. We will now discuss an evidence-based work-up. 36

Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 37

Diagnostic Imaging: ACR Guidelines American College of Radiology Appropriateness Criteria 2010 MR has greater sensitivity than CT for detecting HCC especially in cirrhotic livers and is recommended for diagnostic imaging. 38

Diagnostic Imaging: Liver Protocol Liver imaging for both MRI and CT uses a liver protocol which includes a non-contrast study followed by 3 phase contrast-enhanced liver imaging: - Arterial phase - Venous phase - Delayed phase Radiology. 2008;247:311-330 39

Diagnostic Imaging: Characteristic Findings for HCC on MRI There are several findings that suggest that a liver lesion is HCC on MRI including: - The lesion is hypointense on T1 - The lesion is hyperintense on T2 - The lesion shows enhancement on arterial phase with iso- or hypointensity on venous and delayed phases ( washout ) *Arterial phase enhancement with delayed phase washout is the most specific finding and is part of the radiologic diagnostic criteria for HCC. Radiology. 2008;247:311-330 40

Diagnostic Imaging: Explanation for Arterial enhancement Liver tissue typically receives most of its blood supply from the portal system with a smaller portion from the hepatic artery. In HCC, neoangiogenesis alters that basic relationship. There is a diminution of portal tracts and virtually all of the blood supply is via the hepatic artery. This specific findings allows for distinction from regenerating or dysplastic nodules which can otherwise closely mimic HCC on imaging. Radiology. 2008;247:311-330 41

We have discussed characteristic imaging findings for HCC. Now let s look at some companion patients with HCC on MRI and CT. 42

Companion Patient 7: HCC on MRI Axial T1 arterial phase Axial T1 venous phase Finding: Two liver lesions with arterial enhancement with venous and delayed phase washout. Axial T1 delayed phase Radiology. 2008;247:311-330 43

Companion Patient 3: HCC on MRI Axial T1 pre-contrast Axial T1 arterial phase PACS BIDMC Axial T1 venous phase Axial T1 delayed phase 44

Companion Patient 3: HCC on MRI Finding: A 3.0 cm liver lesion near the falciform ligament is iso-intense on pre-contrast T1 imaging and shows arterial enhancement with venous and delayed phase washout on contrast imaging 45

Companion Patient 3: HCC on CT Axial CT arterial phase Axial CT delayed phase PACS BIDMC Findings: CT shows same classic findings as MR: arterial enhancement with delayed phase washout. 46

We have learned classic examples of HCC on T1 multiphase MRI and on multiphase CT. Now let s examine our index patient s MRI exam. 47

Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 48

Index Patient: HCC on MRI Axial T1 arterial phase Axial T1 venous phase PACS BIDMC Axial T1 delay 1 phase Axial T1 delay 2 phase 49

Index Patient: MRI Findings Findings: - Nodular cirrhotic liver. - 2.1 cm lesion in segment IVa. - The lesion isointense in T1 and T2 (not shown) but shows arterial enhancement and washout pattern in venous and delayed phases (with significant motion artifact) 50

Index Patient: Diagnosis of HCC Our index patient has 1. A lesion greater than 2cm AND 2. Arterial enhancement with venous and delayed phase washout. Based on these findings, a diagnosis of HCC can be made. What are our patient s treatment options? 51

Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 52

Treatment: Surgical resection Depends on the number, size, and location, as well as the patient's functional status. 1. Surgical resection A. favor for lesions which are in a good location and for suitable surgical candidates. B. Can be curative but leaves the patient with a susceptible liver. 2. Liver transplant 3. Minimally invasive/local-regional treatment NEJM. 2011;365:1118-27. 53

Treatment: Transplant Depends on the number, size, and location, as well as the patient's functional status. 1. Surgical resection 2. Liver transplant A. Equivalent or better outcomes than surgical resection B. Patient must meet Milan criteria - one lesion smaller than 5cm. - up to 3 lesions smaller than 3 cm. - no extrahepatic manifestations - no vascular invasion 3. Minimally invasive local-regional treatment NEJM. 2011;365:1118-27. 54

Treatment: Local Therapy Depends on the number, size, and location, as well as the patient's functional status. 1. Surgical resection 2. Liver transplant 3. Minimally invasive local-regional treatment - 1. Useful in certain patient populations (ie poor performance status, expected to receive a transplant in the future) 2. Short-term outcomes are excellent, but long-term outcomes are inferior to above treatments. 3. Methods include: - Transarterial chemoembolization [TACE] - Percutaneous ethanol infusion (PEI) - Radiofrequency ablation (RFA) - Cryotherapy NEJM. 2011;365:1118-27. 55

Index Patient: Radiofrequency Ablation -Our patient was not a good surgical candidate and opted to undergo radiofrequency ablation. -Under ultrasound guidance, a 20-cm long RF electrode was advanced to the site of the lesion and two 12 minute 1200 mamp ablations were performed. Axial non-contrast CT Axial non-contrast CT PACS BIDMC 56

Index Patient: Post-RFA Post-RFA Findings: -Ablation zone measuring 25 x 41 mm surrounded by reactive hyperemia. Axial non-contrast CT PACS BIDMC 57

Index Patient: Follow-up - One month later the patient had ultrasound and CT which showed no new concerning lesions. - He is scheduled for additional ultrasound and CT in three months and is currently clinically stable. 58

Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 59

Summary - Hepatocellular carcinoma is a common cancer associated with cirrhosis and viral hepatitis. Its incidence is increasing. - Surveillance ultrasound every 3-6 months is recommended for all patients with cirrhosis and many patients with HBV. - Concerning lesions on screening ultrasound should be followed up with MRI which has higher sensitivity for assessing lesions than CT particularly in cirrhotic livers. -Arterial enhancement with venous and delayed phase washout is highly specific for HCC. - There are numerous treatment options for HCC which are selected based on the number, size, and location of lesions, as well as the patient's functional status 60

Student Name, year Acknowledgements Dr. Michael Acord Dr. Wei Dr. Gillian Lieberman 61

Student Name, year References El-Serag HB. Current concepts: Hepatocellular carcinoma. NEJM. 2011;365:1118-27. Irshad A, Munazza A, and Ackerman SJ. Current role of ultrasound in chronic liver disease: surveillance, diagnosis, and management of hepatic neoplasms. Curr Probl Diagn Radiol. 2012;41:43-51. Willatt, JM, Hussain HK, Adusumilli A, et al. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early stage hepatocellular carcinoma in patients with cirrhosis. Alimentary Pharmacology and Therapeutics. 2009;30:37-47 AASLD Practice Guideline, Management of Hepatocellular Carcinoma: An Update. Bruix, J, Sherman, M. http://www.aasld.org/practiceguidelines/documents/bookmarked%20practice%20 Guidelines/HCCUpdate2010.pdf Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417 422. Von Herbay A, Frieling T, Niederau C, et al. Solitary hepatic lesions with a hypoechoic rim: value of color Doppler sonography. AJR. 1997;169:1539-1541. Libbrecht L, Bielen D, Verslype C. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl. 2002;8:749. Liver lesion initial characterization. American College of Radiology ACR Appropriateness Criteria. 2010. Medscape. http://www.medscape.com/content/2003/00/44/98/449855/449855_fig.html. (Accessed 2/20/2012) Ultrasoundpaedia: A portal to the world of ultrasound. http://www.ultrasoundpaedia.com/normalliver2/ (Accessed 2/20/2012) 62